<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group>
<journal-title>PLoS ONE</journal-title></journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PONE-D-13-16396</article-id>
<article-id pub-id-type="doi">10.1371/journal.pone.0076799</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories>
<title-group>
<article-title>Can Antidepressants Prevent Pegylated Interferon-α/Ribavirin-Associated Depression in Patients with Chronic Hepatitis C: Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials?</article-title>
<alt-title alt-title-type="running-head">Antidepressants Prevent Depression in Hepatitis C</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hou</surname><given-names>Xin-Jiang</given-names></name><xref ref-type="aff" rid="aff1"/></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Xu</surname><given-names>Jing-Hang</given-names></name><xref ref-type="aff" rid="aff1"/></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Wang</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="aff1"/></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yu</surname><given-names>Yan-Yan</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
</contrib-group>
<aff id="aff1"><addr-line>Department of Infectious Diseases, Peking University First Hospital, Peking University, Beijing, People's Republic of China</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Yu</surname><given-names>Ming-Lung</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group>
<aff id="edit1"><addr-line>Kaohsiung Medical University Hospital, Kaohsiung Medical University, Taiwan</addr-line></aff>
<author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">yyy@bjmu.edu.cn</email></corresp>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn>
<fn fn-type="con"><p>Conceived and designed the experiments: XJH YYY. Performed the experiments: XJH JHX. Analyzed the data: XJH JW. Contributed reagents/materials/analysis tools: JHX JW. Wrote the paper: XJH YYY.</p></fn>
</author-notes>
<pub-date pub-type="collection"><year>2013</year></pub-date>
<pub-date pub-type="epub"><day>30</day><month>10</month><year>2013</year></pub-date>
<volume>8</volume>
<issue>10</issue>
<elocation-id>e76799</elocation-id>
<history>
<date date-type="received"><day>17</day><month>4</month><year>2013</year></date>
<date date-type="accepted"><day>28</day><month>8</month><year>2013</year></date>
</history>
<permissions>
<copyright-year>2013</copyright-year>
<copyright-holder>Hou et al</copyright-holder><license xlink:type="simple"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions>
<abstract><sec>
<title>Background</title>
<p>Antidepressants are effective in treating interferon-α/ribavirin (IFN-α/RBV)-associated depression during or after treatment of chronic hepatitis C (CHC). Whether antidepressant prophylaxis is necessary in this population remains under debate.</p>
</sec><sec>
<title>Methods</title>
<p>Comprehensive searches were performed in Medline, Embase, Cochrane Controlled Trials Register and PubMed. Reference lists were searched manually. The methodology was in accordance with the 2009 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) Statement.</p>
</sec><sec>
<title>Results</title>
<p>We identified six randomized, double-blind, placebo-controlled trials involving 522 CHC patients treated with pegylated (PEG)-IFN-α plus RBV. The antidepressants used were escitalopram, citalopram, and paroxetine, which are selective serotonin reuptake inhibitors (SSRIs). The rates of depression (17.9% vs. 31.0%, P = 0.0005), and rescue therapy (27.4% vs. 42.7%, P&lt;0.0001) in the SSRI group were significantly lower than those in the placebo group. The rate of sustained virological response (SVR) (56.8% vs. 50.0%, P = 0.60) and drug discontinuation (18.7% vs. 21.1%, P = 0.63) in the SSRI group did not differ significantly to those in the placebo group. In terms of safety, the incidence of muscle and joint pain (40.8% vs. 52.4%, P = 0.03) and respiratory problems (29.3% vs. 40.1%, P = 0.03) were lower, but the incidence of dizziness was significantly higher (22.3% vs. 10.2%, P = 0.001) in the SSRI group.</p>
</sec><sec>
<title>Conclusion</title>
<p>Prophylactic SSRI antidepressants can significantly reduce the incidence of PEG-IFN-α/RBV-associated depression in patients with CHC, with good safety and tolerability, without reduction of SVR.</p>
</sec></abstract>
<funding-group><funding-statement>The authors have no support or funding to report.</funding-statement></funding-group><counts><page-count count="8"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>Globally, hepatitis C virus (HCV) has become one of the leading causes of chronic liver diseases and affects &gt;170 million people <xref ref-type="bibr" rid="pone.0076799-Shepard1">[1]</xref>, <xref ref-type="bibr" rid="pone.0076799-Lavanchy1">[2]</xref>. The severity of the disease associated with HCV infection varies from asymptomatic chronic infection to all types of end-stage liver diseases, including cirrhosis and hepatocellular carcinoma <xref ref-type="bibr" rid="pone.0076799-Perz1">[3]</xref>. To date, combination of pegylated interferon-α (PEG-IFN-α) plus ribavirin (RBV) is considered to be the most effective treatment for chronic hepatitis C (CHC). It is recommended in the American Association for the Study of Liver Diseases (AASLD) practical guidelines <xref ref-type="bibr" rid="pone.0076799-Ghany1">[4]</xref>.</p>
<p>However, IFN-α-based therapy is associated with an approximately 70% incidence of mild to moderate depressive syndromes <xref ref-type="bibr" rid="pone.0076799-Reichenberg1">[5]</xref>–<xref ref-type="bibr" rid="pone.0076799-Schfer1">[7]</xref> and 20–40% incidence of major depression in HCV patients <xref ref-type="bibr" rid="pone.0076799-Schfer1">[7]</xref>. IFN-associated depression can lead to deterioration in quality of life, and has become a major contribution to treatment withdrawal, non-compliance, dose reduction of IFN/RBV, and even attempted suicide <xref ref-type="bibr" rid="pone.0076799-Kraus1">[8]</xref>–<xref ref-type="bibr" rid="pone.0076799-Guadagnino1">[15]</xref>; all of which can result in treatment failure <xref ref-type="bibr" rid="pone.0076799-McHutchison1">[16]</xref>–<xref ref-type="bibr" rid="pone.0076799-Shiffman1">[18]</xref>. Furthermore, depressive symptoms are closely related to poor virological response <xref ref-type="bibr" rid="pone.0076799-Raison1">[19]</xref>, <xref ref-type="bibr" rid="pone.0076799-Maddock1">[20]</xref>. Therefore, there is urgency in preventing the occurrence of depression in IFN-α-based therapy.</p>
<p>Although some studies have reported that antidepressants are effective in treating IFN-α/RBV-associated depression during or after treatment of CHC <xref ref-type="bibr" rid="pone.0076799-Hauser1">[21]</xref>–<xref ref-type="bibr" rid="pone.0076799-Morasco1">[29]</xref>, whether antidepressant prophylaxis is necessary in this population remains a subject for debate <xref ref-type="bibr" rid="pone.0076799-Gleason2">[26]</xref>–<xref ref-type="bibr" rid="pone.0076799-Kraus4">[36]</xref>.</p>
<p>Consequently, the aim of this meta-analysis was to evaluate the efficacy and safety of pretreatment with antidepressants to prevent IFN-α/RBV-associated depression in patients with CHC treated with antiviral therapy in randomized, double-blind, placebo-controlled trials.</p>
</sec><sec id="s2" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="s2a">
<title>Literature search</title>
<p>Two authors performed a literature search on Medline (1966 to March 2013), PubMed (updated to March 2013), Embase (1980 to March 2013), and Cochrane Controlled Trials Register (Cochrane Library Issue 1, 2013) using the keywords “hepatitis C AND interferon AND depression”. A manual search of publications and manual review of major journals in internal medicine, gastroenterology, hepatology, and infectious diseases (2000–2012) were also performed. This meta-analysis was conducted and reported according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) Statement issued in 2009 <xref ref-type="bibr" rid="pone.0076799-Moher1">[37]</xref>.</p>
</sec><sec id="s2b">
<title>Inclusion/exclusion criteria</title>
<p>Inclusion criteria were: (1) study population with CHC; (2) antiviral regime was IFN-&lt;alpha&gt;/RBV combination therapy; (3) studies that reported data for outcomes at the end of treatment and follow-up period; (4) studies with full text; and (5) English studies. Exclusion criteria were: (1) non-randomized controlled trials (RCTs); (2) non-prophylaxis studies with pretreatment with antidepressants before antiviral therapy; (3) studies about human immunodeficiency virus, hepatitis B virus or other virus co-infections; and (4) studies about organ transplantation.</p>
</sec><sec id="s2c">
<title>Data extraction</title>
<p>Two investigators independently evaluated each study, each of whom was blinded to the other. Any discrepancy was resolved through discussion. Extracted information included study characteristics (first author, study location, and year); patient baseline characteristics (sex, risk factors, baseline HCV RNA, HCV genotype, body mass index, and percentage with fibrosis and cirrhosis); and antidepressant and antiviral regimens. Outcomes included: total number of patients; number of patients with IFN-associated depression at the end of treatment; number of patients with sustained virological response (SVR) at the end of follow-up (defined as undetectable HCV RNA at the end of follow-up); total number of patients with treatment discontinuation; number of patients with serious adverse events; number of patients with dose reduction due to adverse events; and number of patients who received antidepressant rescue treatment.</p>
</sec><sec id="s2d">
<title>Quality of methodology</title>
<p>Assessment of the methodological quality of the trials was based on the Jadad composite scale <xref ref-type="bibr" rid="pone.0076799-Jadad1">[38]</xref>, which evaluated randomization, concealment and reporting of patient withdrawal and dropout rates, with ≥3 scores defined as high quality, and ≤2 as low quality. Heterogeneity was assessed for each analysis. The methodological quality was assessed independently by two of the authors.</p>
</sec><sec id="s2e">
<title>Statistical methods</title>
<p>The statistical analyses were conducted and Forest plots were generated using RevMan 5.2.3 (Nordic Cochrane Center, Rigshospitalet, Copenhagen, Denmark). The primary endpoints were the rate of incidence of depression and the rate of SVR. The secondary endpoints were the rate of drug discontinuation or withdrawal, rate of antidepressant rescue treatment, and the rate of adverse events. For the calculation of risk ratios (RRs), patients assigned to prophylactic antidepressant treatment were compared with those assigned to placebo in the same trial. The RRs were calculated along with their respective 95% confidence intervals (CIs) and presented for each individual study. Statistical heterogeneity between trials was evaluated by the χ<sup>2</sup> and I<sup>2</sup> tests, with significance being set at P&lt;0.10. In the absence of significant heterogeneity (P&gt;0.10), the fixed-effect method was used to combine the results. When heterogeneity was confirmed (P≤0.10), the random-effect method was used, and sensitivity analyses and meta-regressions were performed with study characteristics to evaluate potential sources of heterogeneity. Stratified analyses were performed using the variables found to be statistically significant in the meta-regressions. Any potential publication bias was evaluated by inspecting funnel plots and the Begg–Mazumdar test <xref ref-type="bibr" rid="pone.0076799-Begg1">[39]</xref>.</p>
</sec></sec><sec id="s3">
<title>Results</title>
<sec id="s3a">
<title>Search results</title>
<p>Of the 871 articles found after initial searching, <underline>six</underline> studies involving 522 patients met the inclusion criteria <xref ref-type="bibr" rid="pone.0076799-Morasco1">[29]</xref>–<xref ref-type="bibr" rid="pone.0076799-Schaefer4">[34]</xref>. A flow chart summarizing the search and screening process is presented in <xref ref-type="fig" rid="pone-0076799-g001">Figure 1</xref>. Placebo-controlled design and intention-to-treat analysis were conducted in all trials. The antidepressants used in the present meta-analysis were escitalopram, citalopram, and paroxetine, all of which <underline>are</underline> selective serotonin reuptake inhibitors (SSRIs). The antiviral therapies administrated in all studies were PEG-IFN-α/RBV, with exception of IFN-α/RBV in some patients in two studies. The baseline patient characteristics and depression scoring system are listed in <xref ref-type="table" rid="pone-0076799-t001">Table 1</xref>. Study design and antidepressant and antiviral regimens are listed in <xref ref-type="table" rid="pone-0076799-t002">Table 2</xref>.</p>
<fig id="pone-0076799-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0076799.g001</object-id><label>Figure 1</label><caption>
<title>Flow diagram of literature search and selection process.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0076799.g001" position="float" xlink:type="simple"/></fig><table-wrap id="pone-0076799-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0076799.t001</object-id><label>Table 1</label><caption>
<title>Basic Characteristics and Depression Assessing System Applied in Trials Included in the Meta-Analysis.</title>
</caption><alternatives><graphic id="pone-0076799-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0076799.t001" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Study</td>
<td align="left" rowspan="1" colspan="1">Status of CHC</td>
<td align="left" rowspan="1" colspan="1">Status of Depression</td>
<td align="left" rowspan="1" colspan="1">Measures for Depression Assessment</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Morasco BJ <xref ref-type="bibr" rid="pone.0076799-Morasco1">[29]</xref></td>
<td align="left" rowspan="1" colspan="1">&gt;18 years old, eligible for IFN/RBV therapy.</td>
<td align="left" rowspan="1" colspan="1">Exclusion criteria: hypersensitivity to paroxetine, active delirium, current major depressive disorder, bipolar disorder, a schizophrenia-spectrum disorder, and a substance use disorder within the last six months.</td>
<td align="left" rowspan="1" colspan="1">DSM-IV (SCID) HAM-D</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Raison CL <xref ref-type="bibr" rid="pone.0076799-Raison2">[30]</xref></td>
<td align="left" rowspan="1" colspan="1">18–65 years old, Exclusion criteria: other liver disease, unstable cardiovascular, endocrinologic, haematologic, renal or neurologic disease.</td>
<td align="left" rowspan="1" colspan="1">Exclusion criteria: history of schizophrenia or bipolar disorder, diagnosis of major depression or substance, abuse/dependence within 6 months of study entry.</td>
<td align="left" rowspan="1" colspan="1">SCID MADRS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Diez-Quevedo C <xref ref-type="bibr" rid="pone.0076799-DiezQuevedo1">[31]</xref></td>
<td align="left" rowspan="1" colspan="1">18–65 years old, ≥16 months of persistent elevated ALT. Exclusion criteria: other liver disease, unstable cardiovascular, endocrinologic, haematologic, renal, autoimmune, neurologic disease, Co-infection with HBV, HIV, neutrophil count&lt;1500,platelet count &lt;70,000 per µl, hemoglobin&lt;12 g/dl in men and &lt;11 g/dl in women, non reliable contraception in women.</td>
<td align="left" rowspan="1" colspan="1">Exclusion criteria: history or current diagnosis of schizophrenia or bipolar disorder, dementia; the presence, within 2 months of study entry, of drug, or alcohol abuse, symptomatic mental disorders(including major depressive disorders, dysthymia, and anxiety disorders other than specific phobias),the use of any psychiatric medication(patients were only allowed to maintain treatments with benzodiazepines at constant dosages). Zolpidem was used for insomnia when needed.</td>
<td align="left" rowspan="1" colspan="1">DSM-IV</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">De Knegt RJ <xref ref-type="bibr" rid="pone.0076799-DeKnegt1">[32]</xref></td>
<td align="left" rowspan="1" colspan="1">18–70 years old, Exclusion criteria: presence of contra-indications, for anti-viral therapy, abnormal values for thyroid stimulating hormone.</td>
<td align="left" rowspan="1" colspan="1">Exclusion criteria: a concurrent psychiatric axis I diagnosis, concurrent use of psychotropic drugs, a history or other evidence of severe illness or malignancy and any other condition which would make the patient unsuitable for the study.</td>
<td align="left" rowspan="1" colspan="1">M.I.N.I. DSM-IV MADRS BDI SCL-90</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Morasco BJ <xref ref-type="bibr" rid="pone.0076799-Morasco2">[33]</xref></td>
<td align="left" rowspan="1" colspan="1">≥18 years old, eligible for antiviral therapy.</td>
<td align="left" rowspan="1" colspan="1">Exclusion criteria: ongoing depression or active psychotic symptoms during the previous 3 months, substance abuse in the previous 6 months, medical comorbidities that could interfere with treatment, or current antidepressant use.</td>
<td align="left" rowspan="1" colspan="1">DSM-IV (SCID) MADRS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Schaefer M <xref ref-type="bibr" rid="pone.0076799-Schaefer4">[34]</xref></td>
<td align="left" rowspan="1" colspan="1">&gt;18 years old, treatment-naive patients, serum HCV RNA levels ≥1000 IU/mL. Exclusion criteria: pretreatment with IFN or immunotherapy, other chronic infection, or an autoimmune or severe somatic comorbid condition.</td>
<td align="left" rowspan="1" colspan="1">Exclusion criteria: a lifetime diagnosis of an affective disorder, drug abuse in the past 12 months, treatment with antidepressants during the past 3 years, or a history of any other axis I disorder.</td>
<td align="left" rowspan="1" colspan="1">DSM-IV (SCID) MADRS</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt101"><label/><p>HBV: Heptatitis B virus, HIV: Human Immunodeficiency Virus, DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, M.I.N.I: Mini-international Neuropsychiatric Interview, SCID: Structured Clinical Interview for DSM–IV; MADRS: Montgomery–Asberg Depression Rating Scale, BDI: Beck Depression Inventory, SCL-90:Symptom Check List-90.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0076799-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0076799.t002</object-id><label>Table 2</label><caption>
<title>Characteristic of Randomized Controlled Trials Included in the Meta-Analysis.</title>
</caption><alternatives><graphic id="pone-0076799-t002-2" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0076799.t002" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Study</td>
<td align="left" rowspan="1" colspan="1">Study design</td>
<td align="left" rowspan="1" colspan="1">SSRI</td>
<td align="left" rowspan="1" colspan="1">Anti depression regime</td>
<td align="left" rowspan="1" colspan="1">Antiviral regime</td>
<td align="left" rowspan="1" colspan="1">Sample size (AD/control)</td>
<td align="left" rowspan="1" colspan="1">Quality Score</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Morasco BJ <xref ref-type="bibr" rid="pone.0076799-Morasco1">[29]</xref></td>
<td align="left" rowspan="1" colspan="1">multi-center, double-blind, placebo-controlled.</td>
<td align="left" rowspan="1" colspan="1">Paroxetine</td>
<td align="left" rowspan="1" colspan="1">4 weeks of prophylaxis, subsequent 24–48weeks of administration.</td>
<td align="left" rowspan="1" colspan="1">genotype-based dose of PEG-IFN-α2a,2b or IFN-α, weight-based dose of RBV.</td>
<td align="left" rowspan="1" colspan="1">14/19</td>
<td align="left" rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Raison CL <xref ref-type="bibr" rid="pone.0076799-Raison2">[30]</xref></td>
<td align="left" rowspan="1" colspan="1">multi-center, double-blind, placebo-controlled.</td>
<td align="left" rowspan="1" colspan="1">Paroxetine</td>
<td align="left" rowspan="1" colspan="1">2 weeks of prophylaxis, subsequent 24 weeks of administration.</td>
<td align="left" rowspan="1" colspan="1">PEG-IFN-2α, 2b or IFN-α, RBV according to treating Physicians.</td>
<td align="left" rowspan="1" colspan="1">28/33</td>
<td align="left" rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Diez-Quevedo C <xref ref-type="bibr" rid="pone.0076799-DiezQuevedo1">[31]</xref></td>
<td align="left" rowspan="1" colspan="1">multi-center, double-blind, placebo-controlled.</td>
<td align="left" rowspan="1" colspan="1">Escitalopram</td>
<td align="left" rowspan="1" colspan="1">2 weeks of prophylaxis, subsequent 14 weeks of administration.</td>
<td align="left" rowspan="1" colspan="1">PEG-IFN-α2a,180 mg/w, RBV 800–1200 mg.</td>
<td align="left" rowspan="1" colspan="1">66/63</td>
<td align="left" rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">De Knegt RJ <xref ref-type="bibr" rid="pone.0076799-DeKnegt1">[32]</xref></td>
<td align="left" rowspan="1" colspan="1">multi-center, double-blind, placebo-controlled.</td>
<td align="left" rowspan="1" colspan="1">Escitalopram</td>
<td align="left" rowspan="1" colspan="1">2 weeks of prophylaxis, subsequent 24 weeks of administration.</td>
<td align="left" rowspan="1" colspan="1">genotype-based dose of PEG-IFN-α2a, weight-based dose of RBV.</td>
<td align="left" rowspan="1" colspan="1">40/39</td>
<td align="left" rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Morasco BJ <xref ref-type="bibr" rid="pone.0076799-Morasco2">[33]</xref></td>
<td align="left" rowspan="1" colspan="1">double-center, double-blind, placebo-controlled.</td>
<td align="left" rowspan="1" colspan="1">Citalopram</td>
<td align="left" rowspan="1" colspan="1">2 weeks of prophylaxis, subsequent 24–48weeks of administration.</td>
<td align="left" rowspan="1" colspan="1">genotype-based dose of PEG-IFN-α. guideline-based dose of RBV.</td>
<td align="left" rowspan="1" colspan="1">19/20</td>
<td align="left" rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Schaefer M <xref ref-type="bibr" rid="pone.0076799-Schaefer4">[34]</xref></td>
<td align="left" rowspan="1" colspan="1">multi-center, double-blind, placebo-controlled.</td>
<td align="left" rowspan="1" colspan="1">Escitalopram</td>
<td align="left" rowspan="1" colspan="1">2 weeks of prophylaxis, subsequent 24–48weeks of administration.</td>
<td align="left" rowspan="1" colspan="1">genotype-based dose of PEG-IFN-α2a,weight-based dose of RBV.</td>
<td align="left" rowspan="1" colspan="1">90/91</td>
<td align="left" rowspan="1" colspan="1">5</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt102"><label/><p>SSRI: selective serotonin reuptake inhibitor; study quality was evaluated on the 7-item Jadad scale, with a range of 0–5.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b">
<title>Rate of depression</title>
<p>All six trials provided data about the rate of PEG-IFN-α/RBV-associated depression. The SSRI group included 252 patients with a rate of depression of 17.9%, while the placebo group included 261 patients with a rate of depression of 31.0%. The test for heterogeneity of the data obtained a P value of 0.27, thus the hypothesis of homogeneity was achieved. An estimated RR of 0.58 (95% CI: 0.43–0.79) was obtained after the data were pooled, and a significant effect on the rate of depression was found for the prophylaxis of SSRIs to prevent PEG-IFN-α/RBV-associated depression in patients with CHC (P = 0.0005) (<xref ref-type="fig" rid="pone-0076799-g002">Figure 2</xref>). The subgroup analyses of different SSRIs for the rate of depression are shown in <xref ref-type="table" rid="pone-0076799-t003">Table 3</xref>.</p>
<fig id="pone-0076799-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0076799.g002</object-id><label>Figure 2</label><caption>
<title>The effect of antidepressant on the incidence of depression.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0076799.g002" position="float" xlink:type="simple"/></fig><table-wrap id="pone-0076799-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0076799.t003</object-id><label>Table 3</label><caption>
<title>Subgroup Analysis with Respect to Antidepressants for Different End-Points.</title>
</caption><alternatives><graphic id="pone-0076799-t003-3" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0076799.t003" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">End-points</td>
<td align="left" rowspan="1" colspan="1">No. of patients with available data</td>
<td align="left" rowspan="1" colspan="1">SSRI group (No./%)</td>
<td align="left" rowspan="1" colspan="1">Placebo group (No./%)</td>
<td align="left" rowspan="1" colspan="1">P for homogeneity/Model</td>
<td align="left" rowspan="1" colspan="1">Exact RR (95%CI)</td>
<td align="left" rowspan="1" colspan="1">P</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Rate of depression</td>
<td align="left" rowspan="1" colspan="1">428/Escitalopram and citalopram</td>
<td align="left" rowspan="1" colspan="1">37/17.2</td>
<td align="left" rowspan="1" colspan="1">69/32.4</td>
<td align="left" rowspan="1" colspan="1">0.24/Fixed</td>
<td align="left" rowspan="1" colspan="1">0.54 [0.38–0.75]</td>
<td align="left" rowspan="1" colspan="1">0.0003</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">389/Escitalopram</td>
<td align="left" rowspan="1" colspan="1">35/17.9</td>
<td align="left" rowspan="1" colspan="1">65/33.7</td>
<td align="left" rowspan="1" colspan="1">0.12/Fixed</td>
<td align="left" rowspan="1" colspan="1">0.54 [0.38–0.76]</td>
<td align="left" rowspan="1" colspan="1">0.0004</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">94/Paroxetine</td>
<td align="left" rowspan="1" colspan="1">8/19.0</td>
<td align="left" rowspan="1" colspan="1">14/26.9</td>
<td align="left" rowspan="1" colspan="1">0.23/Fixed</td>
<td align="left" rowspan="1" colspan="1">0.72 [0.34–1.54]</td>
<td align="left" rowspan="1" colspan="1">0.40</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">474/Escitalopram and Paroxetine</td>
<td align="left" rowspan="1" colspan="1">43/18.5</td>
<td align="left" rowspan="1" colspan="1">77/32.0</td>
<td align="left" rowspan="1" colspan="1">0.17/Fixed</td>
<td align="left" rowspan="1" colspan="1">0.58 [0.43–0.80]</td>
<td align="left" rowspan="1" colspan="1">0.0007</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Rate of SVR</td>
<td align="left" rowspan="1" colspan="1">327/Escitalopram andCitalopram</td>
<td align="left" rowspan="1" colspan="1">93/57.4</td>
<td align="left" rowspan="1" colspan="1">90/54.5</td>
<td align="left" rowspan="1" colspan="1">0.34/Fixed</td>
<td align="left" rowspan="1" colspan="1">1.05 [0.87–1.27]</td>
<td align="left" rowspan="1" colspan="1">0.60</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">288/Escitalopram</td>
<td align="left" rowspan="1" colspan="1">86/59.4</td>
<td align="left" rowspan="1" colspan="1">80/55.2</td>
<td align="left" rowspan="1" colspan="1">0.25/Fixed</td>
<td align="left" rowspan="1" colspan="1">1.09 [0.90–1.33 ]</td>
<td align="left" rowspan="1" colspan="1">0.38</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">321/Escitalopram and Paroxetine</td>
<td align="left" rowspan="1" colspan="1">93/59.2</td>
<td align="left" rowspan="1" colspan="1">82/50.0</td>
<td align="left" rowspan="1" colspan="1">0.05/Random</td>
<td align="left" rowspan="1" colspan="1">1.20 [0.80–1.79]</td>
<td align="left" rowspan="1" colspan="1">0.39</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Rate of discontinuation</td>
<td align="left" rowspan="1" colspan="1">428/Escitalopram and Citalopram</td>
<td align="left" rowspan="1" colspan="1">34/15.8</td>
<td align="left" rowspan="1" colspan="1">30/14.1</td>
<td align="left" rowspan="1" colspan="1">0.28/Fixed</td>
<td align="left" rowspan="1" colspan="1">1.12 [0.71–1.77]</td>
<td align="left" rowspan="1" colspan="1">0.61</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">388/Escitalopram</td>
<td align="left" rowspan="1" colspan="1">31</td>
<td align="left" rowspan="1" colspan="1">25</td>
<td align="left" rowspan="1" colspan="1">0.22/Fixed</td>
<td align="left" rowspan="1" colspan="1">1.22 [0.75–1.99]</td>
<td align="left" rowspan="1" colspan="1">0.43</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">94/Paroxetine</td>
<td align="left" rowspan="1" colspan="1">14/33.3</td>
<td align="left" rowspan="1" colspan="1">26/50.0</td>
<td align="left" rowspan="1" colspan="1">0.71/Fixed</td>
<td align="left" rowspan="1" colspan="1">0.66 [0.40–1.09]</td>
<td align="left" rowspan="1" colspan="1">0.10</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">483/Escitalopram and Paroxetine</td>
<td align="left" rowspan="1" colspan="1">45/18.9</td>
<td align="left" rowspan="1" colspan="1">51/20.8</td>
<td align="left" rowspan="1" colspan="1">0.19/Fixed</td>
<td align="left" rowspan="1" colspan="1">0.95 [0.67–1.35]</td>
<td align="left" rowspan="1" colspan="1">0.78</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Rate of reception of rescue therapy</td>
<td align="left" rowspan="1" colspan="1">389/Escitalopram</td>
<td align="left" rowspan="1" colspan="1">56/28.6</td>
<td align="left" rowspan="1" colspan="1">87/45.1</td>
<td align="left" rowspan="1" colspan="1">0.05/Random</td>
<td align="left" rowspan="1" colspan="1">0.62 [0.50–0.77]</td>
<td align="left" rowspan="1" colspan="1">&lt;0.0001</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt103"><label/><p>SSRI: selective serotonin reuptake inhibitor.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c">
<title>Rate of SVR</title>
<p>Four trials reported data on the effect of antidepressants on SVR. The SSRI group included 176 patients with a rate of SVR of 56.8%, while the placebo group included 184 patients with a rate of SVR of 50.0%. The test for the heterogeneity of the data obtained a P value of 0.08, thus the random model was used. An estimated RR of 1.10 (95% CI: 0.78–1.55) was obtained after the data were pooled. Antidepressant prophylaxis had no significant effect on the rate of SVR in patients with CHC (P = 0.60) (<xref ref-type="fig" rid="pone-0076799-g003">Figure 3</xref>). The subgroup analyses of different SSRIs for the rate of SVR are shown in <xref ref-type="table" rid="pone-0076799-t003">Table 3</xref>.</p>
<fig id="pone-0076799-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0076799.g003</object-id><label>Figure 3</label><caption>
<title>The effect of antidepressant on the SVR.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0076799.g003" position="float" xlink:type="simple"/></fig></sec><sec id="s3d">
<title>Rate of drug discontinuation</title>
<p>All of the trials reported data on drug discontinuation. The SSRI group included 257 patients with a rate of discontinuation of 18.7%, while the placebo group included 265 patients with a rate of discontinuation of 21.1%. The test for heterogeneity of the data obtained a P value of 0.27, thus the hypothesis of homogeneity was achieved. An estimated RR of 0.92 (95% CI: 0.66–1.29) was obtained after the data were pooled. Antidepressant prophylaxis had no significant effect on the rate of discontinuation in patients with CHC (P = 0.63) (<xref ref-type="fig" rid="pone-0076799-g004">Figure 4</xref>). The subgroup analyses of different SSRIs for the rate of discontinuation are shown in <xref ref-type="table" rid="pone-0076799-t003">Table 3</xref>.</p>
<fig id="pone-0076799-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0076799.g004</object-id><label>Figure 4</label><caption>
<title>The comparison of discontinuation.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0076799.g004" position="float" xlink:type="simple"/></fig></sec><sec id="s3e">
<title>Rate of rescue therapy</title>
<p>Four trials reported data on the number of patients receiving rescue therapy. The SSRI group included 215 patients with a rate of rescue therapy of 27.4%, while the placebo group included 213 patients with a rate of rescue therapy of 42.7%. The test for heterogeneity of the data obtained a P value of 0.13, thus the hypothesis of homogeneity was achieved. An estimated RR of 0.63 (95% CI: 0.51–0.78) was obtained after the data were pooled, and a significant effect on the rate of rescue therapy was found (P&lt;0.0001) (<xref ref-type="fig" rid="pone-0076799-g005">Figure 5</xref>). The subgroup analyses of different SSRIs for the rate of rescue therapy are shown in <xref ref-type="table" rid="pone-0076799-t003">Table 3</xref>.</p>
<fig id="pone-0076799-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0076799.g005</object-id><label>Figure 5</label><caption>
<title>The comparison of reception of rescue therapy.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0076799.g005" position="float" xlink:type="simple"/></fig></sec><sec id="s3f">
<title>Adverse events</title>
<p>Data for adverse events were extracted from three trials and subjected to meta-analysis (<xref ref-type="table" rid="pone-0076799-t004">Table 4</xref>). The rate of muscle and joint pain in the SSRI group was significantly lower than that in the placebo group (40.8% vs. 52.4%, P = 0.03). The rate of respiratory problems in the SSRI group was significantly lower than that in the placebo group (29.3% vs. 40.1%, P = 0.03) (<xref ref-type="fig" rid="pone-0076799-g006">Figure 6</xref>). The rate of respiratory problems in the escitalopram group was also significantly lower than that in the placebo group (29.5% vs. 44.2%, P = 0.008) (<xref ref-type="table" rid="pone-0076799-t004">Table 4</xref>). However, the rate of dizziness in the SSRI group was significantly higher than that in the placebo group (22.3% vs. 10.2%, P = 0.001) (<xref ref-type="fig" rid="pone-0076799-g006">Figure 6</xref>). The rate of dizziness in the escitalopram group was also significantly higher than that in the placebo group (19.2% vs. 9.7%, P = 0.02) (<xref ref-type="table" rid="pone-0076799-t004">Table 4</xref>).</p>
<fig id="pone-0076799-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0076799.g006</object-id><label>Figure 6</label><caption>
<title>The comparison of three adverse events.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0076799.g006" position="float" xlink:type="simple"/></fig><table-wrap id="pone-0076799-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0076799.t004</object-id><label>Table 4</label><caption>
<title>Summary of Common Adverse Events associated the Antidepressants and Antiviral Treatment.</title>
</caption><alternatives><graphic id="pone-0076799-t004-4" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0076799.t004" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Adverse events</td>
<td align="left" rowspan="1" colspan="1">No. of patients with available data</td>
<td align="left" rowspan="1" colspan="1">SSRI group (No./%)</td>
<td align="left" rowspan="1" colspan="1">Placebo group (No./%)</td>
<td align="left" rowspan="1" colspan="1">Exact RR (95% CI)</td>
<td align="left" rowspan="1" colspan="1"><italic>P</italic></td>
<td align="left" rowspan="1" colspan="1"><italic>P</italic> for Homogeneity</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Muscle and joint pain</td>
<td align="left" rowspan="1" colspan="1">371(Escitalopram+ Paroxetine)</td>
<td align="left" rowspan="1" colspan="1">75/40.8</td>
<td align="left" rowspan="1" colspan="1">98/52.4</td>
<td align="left" rowspan="1" colspan="1">0.63 [0.42, 0.96]</td>
<td align="left" rowspan="1" colspan="1">0.03</td>
<td align="left" rowspan="1" colspan="1">0.15</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">310(Escitalopram)</td>
<td align="left" rowspan="1" colspan="1">62/39.7</td>
<td align="left" rowspan="1" colspan="1">74/48.1</td>
<td align="left" rowspan="1" colspan="1">0.72 [0.46, 1.12]</td>
<td align="left" rowspan="1" colspan="1">0.14</td>
<td align="left" rowspan="1" colspan="1">0.15</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Dizzness</td>
<td align="left" rowspan="1" colspan="1">371(Escitalopram+ Paroxetine)</td>
<td align="left" rowspan="1" colspan="1">41/22.3</td>
<td align="left" rowspan="1" colspan="1">19/10.2</td>
<td align="left" rowspan="1" colspan="1">2.65 [1.46, 4.80]</td>
<td align="left" rowspan="1" colspan="1">0.001</td>
<td align="left" rowspan="1" colspan="1">0.52</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">310(Escitalopram)</td>
<td align="left" rowspan="1" colspan="1">30/19.2</td>
<td align="left" rowspan="1" colspan="1">15/9.7</td>
<td align="left" rowspan="1" colspan="1">2.26 [1.16, 4.43]</td>
<td align="left" rowspan="1" colspan="1">0.02</td>
<td align="left" rowspan="1" colspan="1">0.57</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Headache</td>
<td align="left" rowspan="1" colspan="1">371(Escitalopram+ Paroxetine)</td>
<td align="left" rowspan="1" colspan="1">61/33.2</td>
<td align="left" rowspan="1" colspan="1">72/38.5</td>
<td align="left" rowspan="1" colspan="1">0.81 [0.53, 1.24]</td>
<td align="left" rowspan="1" colspan="1">0.33</td>
<td align="left" rowspan="1" colspan="1">0.56</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">310(Escitalopram)</td>
<td align="left" rowspan="1" colspan="1">49/31.4</td>
<td align="left" rowspan="1" colspan="1">52/33.8</td>
<td align="left" rowspan="1" colspan="1">0.90 [0.56, 1.45]</td>
<td align="left" rowspan="1" colspan="1">0.67</td>
<td align="left" rowspan="1" colspan="1">0.90</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Fatigue</td>
<td align="left" rowspan="1" colspan="1">371(Escitalopram+ Paroxetine)</td>
<td align="left" rowspan="1" colspan="1">92/50.0</td>
<td align="left" rowspan="1" colspan="1">102/54.5</td>
<td align="left" rowspan="1" colspan="1">0.83 [0.56, 1.25]</td>
<td align="left" rowspan="1" colspan="1">0.38</td>
<td align="left" rowspan="1" colspan="1">0.28</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">310(Escitalopram)</td>
<td align="left" rowspan="1" colspan="1">76/48.7</td>
<td align="left" rowspan="1" colspan="1">87/56.5</td>
<td align="left" rowspan="1" colspan="1">0.73 [0.47, 1.15]</td>
<td align="left" rowspan="1" colspan="1">0.17</td>
<td align="left" rowspan="1" colspan="1">0.42</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Sexual dysfunction</td>
<td align="left" rowspan="1" colspan="1">371(Escitalopram+ Paroxetine)</td>
<td align="left" rowspan="1" colspan="1">17/9.2</td>
<td align="left" rowspan="1" colspan="1">8/4.3</td>
<td align="left" rowspan="1" colspan="1">2.35 [0.98, 5.65]</td>
<td align="left" rowspan="1" colspan="1">0.06</td>
<td align="left" rowspan="1" colspan="1">0.83</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">310(Escitalopram)</td>
<td align="left" rowspan="1" colspan="1">13/8.3</td>
<td align="left" rowspan="1" colspan="1">5/3.2</td>
<td align="left" rowspan="1" colspan="1">2.70 [0.94, 7.82]</td>
<td align="left" rowspan="1" colspan="1">0.07</td>
<td align="left" rowspan="1" colspan="1">0.71</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Loss of appetite</td>
<td align="left" rowspan="1" colspan="1">371(Escitalopram+ Paroxetine)</td>
<td align="left" rowspan="1" colspan="1">37/20.1</td>
<td align="left" rowspan="1" colspan="1">36/19.3</td>
<td align="left" rowspan="1" colspan="1">1.09 [0.65, 1.82]</td>
<td align="left" rowspan="1" colspan="1">0.75</td>
<td align="left" rowspan="1" colspan="1">0.09</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">310(Escitalopram)</td>
<td align="left" rowspan="1" colspan="1">24/15.4</td>
<td align="left" rowspan="1" colspan="1">27/17.5</td>
<td align="left" rowspan="1" colspan="1">0.85 [0.47, 1.55]</td>
<td align="left" rowspan="1" colspan="1">0.60</td>
<td align="left" rowspan="1" colspan="1">0.12</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Sleep disturbance</td>
<td align="left" rowspan="1" colspan="1">371(Escitalopram+ Paroxetine)</td>
<td align="left" rowspan="1" colspan="1">71/38.6</td>
<td align="left" rowspan="1" colspan="1">85/45.5</td>
<td align="left" rowspan="1" colspan="1">0.76 [0.50, 1.15]</td>
<td align="left" rowspan="1" colspan="1">0.19</td>
<td align="left" rowspan="1" colspan="1">0.25</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">310(Escitalopram)</td>
<td align="left" rowspan="1" colspan="1">57/36.5</td>
<td align="left" rowspan="1" colspan="1">71/46.1</td>
<td align="left" rowspan="1" colspan="1">0.68 [0.43, 1.07]</td>
<td align="left" rowspan="1" colspan="1">0.09</td>
<td align="left" rowspan="1" colspan="1">0.26</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Influenza-like illness</td>
<td align="left" rowspan="1" colspan="1">371(Escitalopram+ Paroxetine)</td>
<td align="left" rowspan="1" colspan="1">54/29.3</td>
<td align="left" rowspan="1" colspan="1">64/34.2</td>
<td align="left" rowspan="1" colspan="1">0.81 [0.51, 1.27]</td>
<td align="left" rowspan="1" colspan="1">0.35</td>
<td align="left" rowspan="1" colspan="1">0.58</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">310(Escitalopram)</td>
<td align="left" rowspan="1" colspan="1">42/26.9</td>
<td align="left" rowspan="1" colspan="1">52/33.8</td>
<td align="left" rowspan="1" colspan="1">0.72 [0.43, 1.19]</td>
<td align="left" rowspan="1" colspan="1">0.20</td>
<td align="left" rowspan="1" colspan="1">0.87</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Skin problems</td>
<td align="left" rowspan="1" colspan="1">371 (Escitalopram+ Paroxetine)</td>
<td align="left" rowspan="1" colspan="1">94/51.1</td>
<td align="left" rowspan="1" colspan="1">102/54.5</td>
<td align="left" rowspan="1" colspan="1">0.83 [0.54, 1.29]</td>
<td align="left" rowspan="1" colspan="1">0.42</td>
<td align="left" rowspan="1" colspan="1">0.30</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">310(Escitalopram)</td>
<td align="left" rowspan="1" colspan="1">89/57.1</td>
<td align="left" rowspan="1" colspan="1">92/59.7</td>
<td align="left" rowspan="1" colspan="1">0.90 [0.57, 1.44]</td>
<td align="left" rowspan="1" colspan="1">0.67</td>
<td align="left" rowspan="1" colspan="1">0.20</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Respiratory problems</td>
<td align="left" rowspan="1" colspan="1">371(Escitalopram+ Paroxetine)</td>
<td align="left" rowspan="1" colspan="1">54/29.3</td>
<td align="left" rowspan="1" colspan="1">75/40.1</td>
<td align="left" rowspan="1" colspan="1">0.61 [0.40, 0.94]</td>
<td align="left" rowspan="1" colspan="1">0.03</td>
<td align="left" rowspan="1" colspan="1">0.27</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">310(Escitalopram)</td>
<td align="left" rowspan="1" colspan="1">46/29.5</td>
<td align="left" rowspan="1" colspan="1">68/44.2</td>
<td align="left" rowspan="1" colspan="1">0.53 [0.33, 0.85]</td>
<td align="left" rowspan="1" colspan="1">0.008</td>
<td align="left" rowspan="1" colspan="1">0.78</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Hair loss</td>
<td align="left" rowspan="1" colspan="1">371(Escitalopram+ Paroxetine)</td>
<td align="left" rowspan="1" colspan="1">27/14.7</td>
<td align="left" rowspan="1" colspan="1">33/17.6</td>
<td align="left" rowspan="1" colspan="1">0.80 [0.46, 1.40]</td>
<td align="left" rowspan="1" colspan="1">0.43</td>
<td align="left" rowspan="1" colspan="1">0.38</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">310(Escitalopram)</td>
<td align="left" rowspan="1" colspan="1">24/15.4</td>
<td align="left" rowspan="1" colspan="1">29/18.8</td>
<td align="left" rowspan="1" colspan="1">0.79 [0.43, 1.43]</td>
<td align="left" rowspan="1" colspan="1">0.44</td>
<td align="left" rowspan="1" colspan="1">0.17</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Anemia</td>
<td align="left" rowspan="1" colspan="1">310(Escitalopram)</td>
<td align="left" rowspan="1" colspan="1">23/14.7</td>
<td align="left" rowspan="1" colspan="1">22/14.3</td>
<td align="left" rowspan="1" colspan="1">1.05 [0.56, 1.97]</td>
<td align="left" rowspan="1" colspan="1">0.89</td>
<td align="left" rowspan="1" colspan="1">0.21</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Irritability</td>
<td align="left" rowspan="1" colspan="1">310(Escitalopram)</td>
<td align="left" rowspan="1" colspan="1">16/10.2</td>
<td align="left" rowspan="1" colspan="1">26/16.9</td>
<td align="left" rowspan="1" colspan="1">0.55 [0.28, 1.08]</td>
<td align="left" rowspan="1" colspan="1">0.08</td>
<td align="left" rowspan="1" colspan="1">0.68</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">nausea or vomiting</td>
<td align="left" rowspan="1" colspan="1">371(Escitalopram+ Paroxetine)</td>
<td align="left" rowspan="1" colspan="1">66/35.9</td>
<td align="left" rowspan="1" colspan="1">69/36.9</td>
<td align="left" rowspan="1" colspan="1">0.97 [0.63, 1.48]</td>
<td align="left" rowspan="1" colspan="1">0.88</td>
<td align="left" rowspan="1" colspan="1">0.32</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">310(Escitalopram)</td>
<td align="left" rowspan="1" colspan="1">51/32.7</td>
<td align="left" rowspan="1" colspan="1">56/36.4</td>
<td align="left" rowspan="1" colspan="1">0.85 [0.53, 1.36]</td>
<td align="left" rowspan="1" colspan="1">0.50</td>
<td align="left" rowspan="1" colspan="1">0.42</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Gastrointestinal illness</td>
<td align="left" rowspan="1" colspan="1">371(Escitalopram+ Paroxetine)</td>
<td align="left" rowspan="1" colspan="1">45/24.5</td>
<td align="left" rowspan="1" colspan="1">33/17.6</td>
<td align="left" rowspan="1" colspan="1">1.55 [0.93, 2.58]</td>
<td align="left" rowspan="1" colspan="1">0.09</td>
<td align="left" rowspan="1" colspan="1">0.87</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">310(Escitalopram)</td>
<td align="left" rowspan="1" colspan="1">35/22.4</td>
<td align="left" rowspan="1" colspan="1">24/15.6</td>
<td align="left" rowspan="1" colspan="1">1.57 [0.88, 2.79]</td>
<td align="left" rowspan="1" colspan="1">0.12</td>
<td align="left" rowspan="1" colspan="1">0.60</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt104"><label/><p>SSRI: selective serotonin reuptake inhibitor. Escitalopram+ Paroxetine indicated that one of these two SSRIs was used in one trial and the data on the two SSRIs were meta-analyzed. Escitalopram indicated that data about the antidepressant were meta-analyzed.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4">
<title>Discussion</title>
<p>We performed this meta-analysis of randomized double-blind placebo-controlled clinical trials to evaluate the efficacy and safety of prophylactic antidepressants to prevent PEG-IFN-α/RBV-associated depression in patients with CHC. The results reveal that preemptive and concomitant therapy with SSRIs can significantly reduce the incidence of PEG-IFN-α/RBV-associated depression in patients with CHC. SSRI interventions were safe, did not negatively decrease SVR, and did not influence the rate of drug discontinuation or withdrawal.</p>
<p>Interferon-α/RBV-associated depression is characteristic of a serotonergic deficiency and changes in the serotonin signaling pathway, which requires the prophylactic administration of SSRIs <xref ref-type="bibr" rid="pone.0076799-Schaefer4">[34]</xref>, because these drugs increase serotonin and have been widely used over the past decade, with a good safety profile <xref ref-type="bibr" rid="pone.0076799-Asnis1">[40]</xref>.</p>
<p>The pooled rate of depression in the placebo group was 31.0%, which fell within the 20–40% incidence of depression in patients treated with IFN-α/RBV <xref ref-type="bibr" rid="pone.0076799-Schfer1">[7]</xref>. Compared with placebo, prophylactic antidepressants can significantly reduce the incidence of PEG-IFN-α/RBV-associated depression, by up to 18.7% in CHC patients without a history of severe mental disease. Although standard INF-α was used in some CHC patients in two studies <xref ref-type="bibr" rid="pone.0076799-Morasco1">[29]</xref>, <xref ref-type="bibr" rid="pone.0076799-Raison2">[30]</xref>, the results from the other four trials showed that antidepressants markedly decreased the incidence of depression to 17.2% during PEG-IFN-α-based antiviral therapy. Furthermore, both current types of PEG-IFN-α, that is, PEG-IFN-α2a and 2b, were administrated in all six trials, so the type of IFN-α may be ignored when prophylactic SSRIs are used in patients with CHC. Escitalopram and paroxetine share the same mechanism of action to treat depression, although the former is superior to the latter for prophylactic intervention according to the present study. Escitalopram was developed after citalopram and is considered safer and more effective for treating major depression. However, a previous meta-analysis showed that escitalopram was not superior to citalopram in short-to-medium term treatment of major depressive disorder <xref ref-type="bibr" rid="pone.0076799-Trkulja1">[41]</xref>. The rate of depression was 10.5% when citalopram was used <xref ref-type="bibr" rid="pone.0076799-Morasco2">[33]</xref>, which was lower than 17.9%—the pooled rate of depression in three trials when escitalopram was used <xref ref-type="bibr" rid="pone.0076799-DiezQuevedo1">[31]</xref>, <xref ref-type="bibr" rid="pone.0076799-DeKnegt1">[32]</xref>, <xref ref-type="bibr" rid="pone.0076799-Schaefer4">[34]</xref>. However, the sample size in the trial on citalopram was only 39 patients, which was 10% of the pooled sample in the three trials of escitalopram. Clinically, clinicians should pay more attention to the results of meta-analyses.</p>
<p>With respect to the effect of SSRIs on the SVR, the results varied among the trials, although the trials were of similar design <xref ref-type="bibr" rid="pone.0076799-Morasco1">[29]</xref>, <xref ref-type="bibr" rid="pone.0076799-DiezQuevedo1">[31]</xref>, <xref ref-type="bibr" rid="pone.0076799-Morasco2">[33]</xref>, <xref ref-type="bibr" rid="pone.0076799-Schaefer4">[34]</xref>. The pooled SVR rate in the setting of prophylactic SSRIs did not differ significantly compared with that in the placebo group. Subgroup analysis also reached a similar conclusion. Consequently, prophylactic SSRIs have little effect on the SVR in patients with CHC when they are treated with antiviral therapy. However, we suggest that escitalopram should be used because of the higher SVR rate and its increased use for intervention in depression.</p>
<p>IFN-α/RBV-associated depression was an important reason for discontinuing antiviral therapy <xref ref-type="bibr" rid="pone.0076799-Fried1">[42]</xref>, <xref ref-type="bibr" rid="pone.0076799-Manns1">[43]</xref>. Consequently, successful treatment of CHC needs prevention of depression. The pooled rate of drug discontinuation differed significantly between the SSRI and placebo groups after subgroup analyses, which was consistent with the results from each trial individually. These results suggest that prophylactic SSRIs have little effect on drug discontinuation during treatment of CHC with the currently available antiviral therapy.</p>
<p>The lower rates of rescue therapy, muscle and joint pain and respiratory problems in the SSRI group indicated the better safety and tolerability of SSRIs. These results suggest that prophylactic SSRIs reduce the occurrence of these two adverse events associated with PEG-IFN-α/RBV combination therapy in patients with CHC. However, the pooled rate of dizziness was higher in the SSRI group than the placebo group, which was consistent with the results of each separate trial. This reminds clinicians to pay more attention to the occurrence of this adverse event when prophylactic SSRIs are administrated to patients with CHC. Therefore, prophylactic SSRIs did not worsen most adverse events apart from dizziness. Moreover, adverse events (e.g. diarrhea, headache, and sleep disturbance) were not increased as a result of concurrent administration of antiviral therapy and SSRIs. Although it was reported that citalopram could be safely used during IFN treatment in patients with CHC <xref ref-type="bibr" rid="pone.0076799-Gleason4">[44]</xref>, there were risks of using SSRIs during IFN treatment, because CHC may alter the pharmacokinetics of SSRIs. Therefore, SSRI dose may require adjustment to optimize the treatment <xref ref-type="bibr" rid="pone.0076799-Asnis1">[40]</xref>.</p>
<p>We need to emphasize that according to our clinical experience and inclusion criteria, the optimal candidates for SSRI prophylaxis are CHC patients with concurrent subsyndromal depression symptoms (such as insomnia and anxiety) or a history of past major depressive disorders and eligibility for PEG-IFN-α/RBV treatment.</p>
<p>There were several limitations to our study. First, only six eligible RCTs were included, and we were limited by data availability. Second, sample sizes in most of the trials were small and included &lt;50 subjects. Third, the possibility of omission of unpublished or ongoing studies still exist, although publication bias was not found according to the funnel plots and the Begg–Mazumdar test. Fourth, possible variation in the definition of depression and severity of depression were present in the studies included in our analysis, although the criteria for diagnosis and severity of depression were similar in all studies. These defects may weaken our results. Further analysis of increased numbers of multicenter RCTs with larger sample sizes are warranted to evaluate comprehensively the true value of prophylactic SSRIs to prevent PEG-IFN-α/RBV-associated depression during antiviral therapy in patients with CHC.</p>
<p>Despite these limitations, our meta-analysis of double-blind, placebo-controlled RCTs shows that prophylactic SSRIs can significantly reduce the incidence of PEG-IFN-α/RBV-associated depression in patients with CHC, with good safety and tolerability and without reduction of SVR.</p>
</sec><sec id="s5">
<title>Supporting Information</title>
<supplementary-material id="pone.0076799.s001" mimetype="application/msword" xlink:href="info:doi/10.1371/journal.pone.0076799.s001" position="float" xlink:type="simple"><label>Figure S1</label><caption>
<p><bold>PRISMA 2009 Flow Diagram.</bold></p>
<p>(DOC)</p>
</caption></supplementary-material><supplementary-material id="pone.0076799.s002" mimetype="application/msword" xlink:href="info:doi/10.1371/journal.pone.0076799.s002" position="float" xlink:type="simple"><label>Checklist S1</label><caption>
<p><bold>PRISMA 2009 Checklist.</bold></p>
<p>(DOC)</p>
</caption></supplementary-material></sec></body>
<back><ref-list>
<title>References</title>
<ref id="pone.0076799-Shepard1"><label>1</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shepard</surname><given-names>CW</given-names></name>, <name name-style="western"><surname>Finelli</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Alter</surname><given-names>MJ</given-names></name> (<year>2005</year>) <article-title>Global epidemiology of hepatitis C virus infection</article-title>. <source>Lancet Infect Dis</source> <volume>5</volume>: <fpage>558</fpage>–<lpage>67</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Lavanchy1"><label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lavanchy</surname><given-names>D</given-names></name> (<year>2009</year>) <article-title>The global burden of hepatitis C</article-title>. <source>Liver Int</source> <volume>29</volume>: <fpage>74</fpage>–<lpage>81</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Perz1"><label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Perz</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Armstrong</surname><given-names>GL</given-names></name>, <name name-style="western"><surname>Farrington</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Hutin</surname><given-names>YJ</given-names></name>, <name name-style="western"><surname>Bell</surname><given-names>BP</given-names></name> (<year>2006</year>) <article-title>The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide</article-title>. <source>J Hepatol</source> <volume>45</volume>: <fpage>529</fpage>–<lpage>38</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Ghany1"><label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ghany</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Strader</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Seeff</surname><given-names>LB</given-names></name> (<year>2009</year>) <article-title>Diagnosis, management, and treatment of hepatitis C: an update</article-title>. <source>Hepatology</source> <volume>49</volume>: <fpage>1335</fpage>–<lpage>74</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Reichenberg1"><label>5</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Reichenberg</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gorman</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Dieterich</surname><given-names>DT</given-names></name> (<year>2005</year>) <article-title>Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study</article-title>. <source>AIDS</source> <volume>Suppl 3</volume>: <fpage>S174</fpage>–<lpage>8</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Schaefer1"><label>6</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schaefer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Schwaiger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Garkisch</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Pich</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hinzpeter</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C</article-title>. <source>J Hepatol</source> <volume>42</volume>: <fpage>793</fpage>–<lpage>8</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Schfer1"><label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schäfer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Wittchen</surname><given-names>HU</given-names></name>, <name name-style="western"><surname>Seufert</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kraus</surname><given-names>MR</given-names></name> (<year>2007</year>) <article-title>Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C-a critical review</article-title>. <source>Int J Methods Psychiatr Res</source> <volume>16</volume>: <fpage>186</fpage>–<lpage>201</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Kraus1"><label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kraus</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Schafer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Csef</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Faller</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Mork</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition</article-title>. <source>Digest Dis Sci</source> <volume>46</volume>: <fpage>2060</fpage>–<lpage>5</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Zdilar1"><label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zdilar</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Franco-Bronson</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Buchler</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Locala</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Younossi</surname><given-names>ZM</given-names></name> (<year>2000</year>) <article-title>Hepatitis C, interferon alfa, and depression</article-title>. <source>Hepatology</source> <volume>31</volume>: <fpage>1207</fpage>–<lpage>11</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Sockalingam1"><label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sockalingam</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Links</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Abbey</surname><given-names>SE</given-names></name> (<year>2011</year>) <article-title>Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update</article-title>. <source>J Viral Hepat</source> <volume>18</volume>: <fpage>153</fpage>–<lpage>60</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Cacoub1"><label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cacoub</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Ratziu</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Myers</surname><given-names>RP</given-names></name>, <name name-style="western"><surname>Ghillani</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Piette</surname><given-names>JC</given-names></name>, <etal>et al</etal>. (<year>2002</year>) <article-title>Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C</article-title>. <source>J Hepatol</source> <volume>36</volume>: <fpage>812</fpage>–<lpage>8</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Bernstein1"><label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bernstein</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kleinman</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Barker</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Revicki</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Green</surname><given-names>J</given-names></name> (<year>2002</year>) <article-title>Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients</article-title>. <source>J Hepatol</source> <volume>35</volume>: <fpage>704</fpage>–<lpage>8</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Schaefer2"><label>13</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schaefer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Engelbrecht</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Gut</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Fiebich</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Bauer</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2002</year>) <article-title>Interferon alpha (IFNa) and psychiatric syndromes: a review</article-title>. <source>Pro Neuro-Psychopharmacol Biol Psychiatry</source> <volume>26</volume>: <fpage>731</fpage>–<lpage>46</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Dieperink1"><label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dieperink</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Willenbring</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ho</surname><given-names>SB</given-names></name> (<year>2000</year>) <article-title>Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review</article-title>. <source>Am J Psychiatry</source> <volume>157</volume>: <fpage>867</fpage>–<lpage>76</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Guadagnino1"><label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Guadagnino</surname><given-names>VA</given-names></name>, <name name-style="western"><surname>Trotta</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Carioti</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Caroleo</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Antinori</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Does depression symptomatology affect medication compliance during the first weeks of anti-HCV therapy in intravenous drug users?</article-title> <source>Digest Liver Dis</source> <volume>38</volume>: <fpage>119</fpage>–<lpage>24</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-McHutchison1"><label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McHutchison</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Manns</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Poynard</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Lindsay</surname><given-names>KL</given-names></name>, <etal>et al</etal>. (<year>2002</year>) <article-title>Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C</article-title>. <source>Gastroenterol</source> <volume>123</volume>: <fpage>1061</fpage>–<lpage>9</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Davis1"><label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Davis</surname><given-names>GL</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>McHutchison</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Manns</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Harvey</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C</article-title>. <source>Hepatology</source> <volume>38</volume>: <fpage>645</fpage>–<lpage>52</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Shiffman1"><label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shiffman</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Di Bisceglie</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Lindsay</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Morishima</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wright</surname><given-names>EC</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment</article-title>. <source>Gastroenterol</source> <volume>126</volume>: <fpage>1015</fpage>–<lpage>23</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Raison1"><label>19</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Raison</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Broadwell</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Borisov</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Manatunga</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Capuron</surname><given-names>L</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C</article-title>. <source>Brain Behav Immun</source> <volume>19</volume>: <fpage>23</fpage>–<lpage>7</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Maddock1"><label>20</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Maddock</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Landau</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Barry</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Maulayah</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Hotopf</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response</article-title>. <source>Mol Psychiatry</source> <volume>10</volume>: <fpage>332</fpage>–<lpage>3</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Hauser1"><label>21</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hauser</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Khosla</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Aurora</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Laurin</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kling</surname><given-names>MA</given-names></name>, <etal>et al</etal>. (<year>2002</year>) <article-title>A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C</article-title>. <source>Mol Psychiatry</source> <volume>7</volume>: <fpage>942</fpage>–<lpage>7</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Kraus2"><label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kraus</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Schafer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Faller</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Csef</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Scheurlen</surname><given-names>M</given-names></name> (<year>2002</year>) <article-title>Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C</article-title>. <source>Aliment Pharmacol Therap</source> <volume>16</volume>: <fpage>1091</fpage>–<lpage>9</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Schaefer3"><label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schaefer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Schwaiger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Garkisch</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Pich</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hinzpeter</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C</article-title>. <source>J Hepatol</source> <volume>42</volume>: <fpage>793</fpage>–<lpage>8</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Farah1"><label>24</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Farah</surname><given-names>A</given-names></name> (<year>2002</year>) <article-title>Interferon-induced depression treated with citalopram</article-title>. <source>J Clin Psychiatry</source> <volume>63</volume>: <fpage>166</fpage>–<lpage>7</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Gleason1"><label>25</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gleason</surname><given-names>OC</given-names></name>, <name name-style="western"><surname>Yates</surname><given-names>WR</given-names></name> (<year>1999</year>) <article-title>Five cases of interferon-alpha-induced depression treated with antidepressant therapy</article-title>. <source>Psychosom</source> <volume>40</volume>: <fpage>510</fpage>–<lpage>2</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Gleason2"><label>26</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gleason</surname><given-names>OC</given-names></name>, <name name-style="western"><surname>Yates</surname><given-names>WR</given-names></name>, <name name-style="western"><surname>Isbell</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Philipsen</surname><given-names>MA</given-names></name> (<year>2002</year>) <article-title>An open-label trial of citalopram for major depression in patients with hepatitis C</article-title>. <source>J Clin Psychiatry</source> <volume>63</volume>: <fpage>194</fpage>–<lpage>8</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Schramm1"><label>27</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schramm</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Lawford</surname><given-names>BR</given-names></name>, <name name-style="western"><surname>MacdonaldGA, Cooksley</surname><given-names>WG</given-names></name> (<year>2000</year>) <article-title>Sertraline treatment of interferon-alfa-induced depressive disorder</article-title>. <source>Med J Aust</source> <volume>173</volume>: <fpage>359</fpage>–<lpage>61</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Kraus3"><label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kraus</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Schäfer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Schöttker</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Keicher</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Weissbrich</surname><given-names>B</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Therapy of interferon induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study</article-title>. <source>Gut</source> <volume>57</volume>: <fpage>531</fpage>–<lpage>6</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Morasco1"><label>29</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Morasco</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Rifai</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Loftis</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Indest</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Moles</surname><given-names>JK</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C</article-title>. <source>J Affect Disord</source> <volume>103</volume>: <fpage>83</fpage>–<lpage>90</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Raison2"><label>30</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Raison</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Woolwine</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Demetrashvili</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Borisov</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Weinreib</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C</article-title>. <source>Aliment Pharmacol Ther</source> <volume>25</volume>: <fpage>1163</fpage>–<lpage>74</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-DiezQuevedo1"><label>31</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Diez-Quevedo</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Masnou</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Planas</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Castellví</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Giménez</surname><given-names>D</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial</article-title>. <source>J Clin Psychiatry</source> <volume>72</volume>: <fpage>522</fpage>–<lpage>8</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-DeKnegt1"><label>32</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>De Knegt</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Bezemer</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Van Gool</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Drenth</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Hansen</surname><given-names>BE</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferonalfa-2a and ribavirin for chronic hepatitis C</article-title>. <source>Aliment Pharmacol Ther</source> <volume>34</volume>: <fpage>1306</fpage>–<lpage>17</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Morasco2"><label>33</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Morasco</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Loftis</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Indest</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Ruimy</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Davison</surname><given-names>JW</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial</article-title>. <source>Psychosomatics</source> <volume>51</volume>: <fpage>401</fpage>–<lpage>8</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Schaefer4"><label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schaefer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sarkar</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Knop</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Effenberger</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Friebe</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial</article-title>. <source>Ann Intern Med</source> <volume>157</volume>: <fpage>94</fpage>–<lpage>103</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Gleason3"><label>35</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gleason</surname><given-names>OC</given-names></name>, <name name-style="western"><surname>Fucci</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Yates</surname><given-names>WR</given-names></name>, <name name-style="western"><surname>Philipsen</surname><given-names>MA</given-names></name> (<year>2007</year>) <article-title>Preventing relapse of major depression during interferon-alpha therapy for hepatitis C-A pilot study</article-title>. <source>Dig Dis Sci</source> <volume>52</volume>: <fpage>2557</fpage>–<lpage>63</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Kraus4"><label>36</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kraus</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Schäfer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Al-Taie</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Scheurlen</surname><given-names>M</given-names></name> (<year>2005</year>) <article-title>Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression</article-title>. <source>J Viral Hepat</source> <volume>12</volume>: <fpage>96</fpage>–<lpage>100</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Moher1"><label>37</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moher</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Liberati</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Tetzlaff</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name> (<year>2009</year>) <collab xlink:type="simple">PRISMA Group</collab> (<year>2009</year>) <article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title>. <source>PLoS Med</source> <volume>6</volume>: <fpage>e1000097</fpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Jadad1"><label>38</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jadad</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Moore</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Carroll</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Jenkinson</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Reynolds</surname><given-names>DJ</given-names></name>, <etal>et al</etal>. (<year>1996</year>) <article-title>Assessing the quality of reports of randomized clinical trials: is blindingnecessary?</article-title> <source>Control Clin Trials</source> <volume>17</volume>: <fpage>1</fpage>–<lpage>12</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Begg1"><label>39</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname><given-names>M</given-names></name> (<year>1994</year>) <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source> <volume>50</volume>: <fpage>1088</fpage>–<lpage>101</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Asnis1"><label>40</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Asnis</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>De La Garza</surname><given-names>R</given-names><suffix>2nd</suffix></name> (<year>2006</year>) <article-title>Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches</article-title>. <source>J Clin Gastroenterol</source> <volume>40</volume>: <fpage>322</fpage>–<lpage>35</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Trkulja1"><label>41</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Trkulja</surname><given-names>V</given-names></name> (<year>2010</year>) <article-title>Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials</article-title>. <source>Croat Med J</source> <volume>51</volume>: <fpage>61</fpage>–<lpage>73</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Fried1"><label>42</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fried</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>Shiffman</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Reddy</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Marinos</surname><given-names>G</given-names></name>, <etal>et al</etal>. (<year>2002</year>) <article-title>Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection</article-title>. <source>N Engl J Med</source> <volume>347</volume>: <fpage>975</fpage>–<lpage>82</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Manns1"><label>43</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Manns</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>McHutchison</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Gordon</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Rustgi</surname><given-names>VK</given-names></name>, <name name-style="western"><surname>Shiffman</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial</article-title>. <source>Lancet</source> <volume>358</volume>: <fpage>958</fpage>–<lpage>65</lpage>.</mixed-citation>
</ref>
<ref id="pone.0076799-Gleason4"><label>44</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gleason</surname><given-names>OC</given-names></name>, <name name-style="western"><surname>Yates</surname><given-names>WR</given-names></name>, <name name-style="western"><surname>Philipsen</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Isbell</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Pollock</surname><given-names>BG</given-names></name> (<year>2004</year>) <article-title>Plasma levels of citalopram in depressed patients with hepatitis C</article-title>. <source>Psychosomatics</source> <volume>45</volume>: <fpage>29</fpage>–<lpage>33</lpage>.</mixed-citation>
</ref>
</ref-list></back>
</article>